4.7 Meeting Abstract

Abiraterone acetate plus prednisolone for hormone-naive prostate cancer (PCa): Long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476)

Journal

ANNALS OF ONCOLOGY
Volume 31, Issue -, Pages S509-S509

Publisher

ELSEVIER
DOI: 10.1016/j.annonc.2020.08.871

Keywords

-

Categories

Funding

  1. Janssen
  2. Astellas
  3. Clovis
  4. Sanofi Aventis
  5. Novartis
  6. Pfizer

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available